You are here

Early Onset of Clinical Effects Seen With Glatiramer Therapy

HONOLULU, April 3 /PRNewswire/ -- As early as six months after starting therapy, COPAXONE(R) (glatiramer acetate injection) showed the ability to reduce relapses in relapsing-remitting multiple sclerosis (MS). In addition, benefits were sustained at 12 and 24 months, according to a poster presented this week at the American Academy of Neurology (AAN).

The study evaluated the time of onset of relapse rate reduction for people treated with COPAXONE(R) compared to those treated with other disease modifying therapies. This controlled, open-label study assessed how quickly COPAXONE(R) would begin showing clinical effects, such as relapse rate reduction.

"COPAXONE(R) demonstrated its ability to reduce relapses as early as six months in this study. This is comparable to the interferon data at six months. More significantly, the clinical benefit of COPAXONE(R) continued when reviewed after one year and two years on therapy," said Judith Haas, M.D., Jewish Hospital, Department of Neurology, Berlin, Germany.

The study is an ongoing prospective, controlled, open label trial that is looking at 255 people living with relapsing-remitting MS. At the start of the study, the annualized relapse rates for patients on all of the disease modifying agents were similar, ranging from 1.06 to 1.20. At six months, those taking COPAXONE(R) had a relapse rate reduction of 0.70 compared to baseline (p The COPAXONE(R) (glatiramer acetate injection) relapse rate reduction from baseline continued to improve with reductions of -0.73 at one year and -0.81 at two years, and that lowering was statistically significant than what was measured at the study outset (p COPAXONE(R) is indicated for the reduction of the frequency of relapses in relapsing-remitting MS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, or a lump at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 42 countries worldwide, including the U.S., Canada, Australia, Israel and all the European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd., and Aventis Pharma. In North America, COPAXONE(R) is marketed by Teva Neuroscience.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation